|Mr. Robert J. DeLuccia||Co-Founder & Exec. Chairman||464.77k||N/A||1946|
|Mr. David P. Luci CPA, CPA, Esq., J.D.||Corp. Sec., Co-Founder, Pres, CEO & Director||443.14k||N/A||1967|
|Mr. Robert G. Shawah CPA||Co-Founder & CFO||200.34k||N/A||1967|
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.